C
43.28
0.38 (0.89%)
| Previous Close | 42.90 |
| Open | 42.94 |
| Volume | 933,022 |
| Avg. Volume (3M) | 1,475,014 |
| Market Cap | 4,075,936,768 |
| Price / Sales | 2.67 |
| Price / Book | 3.34 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.88 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 143.00 (JMP Securities, 230.41%) | Buy |
| Median | 77.00 (77.91%) | |
| Low | 40.00 (Goldman Sachs, -7.58%) | Hold |
| Average | 78.43 (81.22%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 43.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 30 Sep 2025 | 87.00 (101.02%) | Buy | 41.65 |
| Leerink Partners | 29 Sep 2025 | 88.00 (103.33%) | Buy | 43.51 |
| Morgan Stanley | 29 Sep 2025 | 77.00 (77.91%) | Buy | 43.51 |
| Baird | 26 Sep 2025 | 62.00 (43.25%) | Buy | 45.91 |
| Goldman Sachs | 26 Sep 2025 | 40.00 (-7.58%) | Hold | 45.91 |
| JMP Securities | 26 Sep 2025 | 143.00 (230.41%) | Buy | 45.91 |
| 11 Aug 2025 | 86.00 (98.71%) | Buy | 27.38 | |
| JP Morgan | 24 Sep 2025 | 52.00 (20.15%) | Buy | 35.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |